Pancreatic Cancer Research

ResearcherNagoya City UniversityActive in the last 2 years

Mamoru Morimoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7837-9642; OpenAlex author ID A5007065982. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers

Papers 11

  1. Expression of ZKSCAN3 protein suppresses proliferation, migration, and invasion of pancreatic cancer through autophagy. Co-author DOI 10.1111/cas.16173↗
  2. The Natural Product Parthenolide Inhibits Both Angiogenesis and Invasiveness and Improves Gemcitabine Resistance by Suppressing Nuclear Factor κB Activation in… Co-author DOI 10.3390/nu16050705↗
  3. Upregulation of integrin‑linked kinase enhances tumor progression in gemcitabine‑resistant pancreatic cancer. Co-author DOI 10.3892/or.2023.8601↗
  4. Girdin regulates both migration and angiogenesis in pancreatic cancer cell lines. Co-author DOI 10.3892/or.2023.8606↗
  5. 10Z‑Hymenialdisine inhibits angiogenesis by suppressing NF‑κB activation in pancreatic cancer cell lines. Co-author DOI 10.3892/or.2022.8259↗
  6. Enhanced CXCL12/CXCR4 signaling increases tumor progression in radiation‑resistant pancreatic cancer. Co-author DOI 10.3892/or.2022.8279↗
  7. Escin inhibits angiogenesis by suppressing interleukin‑8 and vascular endothelial growth factor production by blocking nuclear factor‑κB activation in pancreat… Co-author DOI 10.3892/or.2021.8006↗
  8. Acquisition of gemcitabine resistance enhances angiogenesis via upregulation of IL‑8 production in pancreatic cancer. Co-author DOI 10.3892/or.2019.7105↗
  9. [A Case of Conversion Surgery for an Initially Locally Advanced Unresectable Pancreatic Cancer after S-1 Chemotherapy]. Co-author PMID 32156996↗
  10. Xanthohumol inhibits angiogenesis by suppressing nuclear factor-κB activation in pancreatic cancer. Co-author DOI 10.1111/cas.13441↗
  11. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists. Co-author DOI 10.1186/s12885-016-2340-z↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoichi Matsuo · 11 shared papers, 2016–2024 · strength 1.34
  2. Hiroki Takahashi · 11 shared papers, 2016–2024 · strength 1.34
  3. Kenta Saito · 11 shared papers, 2016–2024 · strength 1.34
  4. Hiroyuki Imafuji · 10 shared papers, 2018–2024 · strength 1.29
  5. Shuji Takiguchi · 10 shared papers, 2018–2024 · strength 1.29
  6. Tomokatsu Kato · 7 shared papers, 2021–2024 · strength 1.04
  7. Hiromichi Murase · 6 shared papers, 2022–2024 · strength 0.93
  8. Yuichi Hayashi · 7 shared papers, 2019–2023 · strength 0.85
  9. Kan Omi · 6 shared papers, 2019–2023 · strength 0.70
  10. Goro Ueda · 6 shared papers, 2019–2023 · strength 0.70
  11. Keisuke Nonoyama · 4 shared papers, 2023–2024 · strength 0.66
  12. Yuki Denda · 4 shared papers, 2023–2024 · strength 0.66
  13. Saburo Sugita · 2 shared papers, 2024 · strength 0.36
  14. Yuki Eguchi · 2 shared papers, 2024 · strength 0.36
  15. Tomoya Shamoto · 2 shared papers, 2016–2018 · strength 0.13
  16. Hiromitsu Takeyama · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.